<DOC>
	<DOCNO>NCT00272831</DOCNO>
	<brief_summary>Patients type 2 diabetes long duration disease development complication . Among complication , microangiopathic complication major cause mortality morbidity diabetic patient . In Asia , patient type 2 diabetes particularly susceptible development kidney disease . Patients diabetic kidney disease adverse metabolic profile increase risk complication blindness , stroke , heart attack nerve damage without . Despite receive best care , combine event rate death , cardiovascular disease end stage kidney disease diabetic patient renal impairment remain high 10 % per year . Cilostazol reduce platelet aggregation prevents formation blood clot . Furthermore , cilostazol treatment show reduce serum triglyceride concentration increase HDL-cholesterol level . In randomized placebo-controlled , double-blinded study , investigator hypothesize Cilostazol may reduce rate decline renal function Chinese patient type 2 diabetes mild moderate renal impairment . Sixty patient randomise receive either Cilostazol 100 mg twice daily placebo 12 month . The effect Cilostazol progression diabetic nephropathy , define rate decline glomerular filtration rate , serum creatinine urinary albumin excretion rate measure . The result provide additional insight management diabetic kidney disease prevalent among Chinese diabetic patient Hong Kong .</brief_summary>
	<brief_title>The Use Cilostazol Patients With Diabetic Nephropathy</brief_title>
	<detailed_description>Hypothesis : Cilostazol reduces rate decline renal function Chinese patient type 2 diabetes mild moderate renal impairment secondary diabetic nephropathy . Objectives : To assess suppressive effect Cilostazol progression diabetic nephropathy , define rate decline glomerular filtration rate , serum creatinine urinary albumin excretion rate . The rise prevalence diabetes Asia imposes heavy burden health care system . Given increasingly early onset disease , patient type 2 diabetes long duration disease development complication . Among complication , microangiopathic complication major cause mortality morbidity diabetic patient . In Asia , patient type 2 diabetes particularly susceptible development nephropathy . Among dialysis patient , primary disease diabetic nephropathy 40 50 % patient . Despite inhibition renin angiotensin system use either ACE inhibitor AII receptor blocker ( ARB ) well introduction tight glycaemic blood pressure control , prevalence diabetic nephropathy remain high . More importantly , patient nephropathy adverse metabolic profile increase risk complication retinopathy , macrovascular disease neuropathy without . Indeed , accord RENAAL Study , despite receive best care , combine event rate death , cardiovascular disease end stage renal disease diabetic patient renal impairment remain high 10 % per year . Cilostazol exert antiplatelet , antithrombotic vasodilating effect inhibit phosphodiesterase type 3 platelet vascular smooth muscle cell . Furthermore , cilostazol treatment show reduce serum triglyceride concentration increase HDL-cholesterol level . In Japanese patient type 2 diabetes , cilostazol therapy associate regression carotid intimal medium thickness could prevent onset silent brain infarction . On hand , abnormal metabolism prostaglandins renal glomerulus postulate modulate renal haemodynamics . Elevated level platelet-derived microparticles soluble adhesion molecule may contribute development diabetic nephropathy . Cilostazol treatment show reduce serum level PMP , activate platelet subset , soluble adhesion molecule urinary excretion thromboxane B2 patient type 2 diabetes . These change accompany reduction urinary albumin excretion increase creatinine clearance .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Diabetes Complications</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>1 . Male female patient age 20 70 year 2 . Patients Type 2 diabetic mellitus 3 . A fasting urinary albumin/creatinine ratio great equal 30 mg/mmol 24 hour urinary albumin excretion great equal 300 mg/day two urine collection baseline period 4 . Two consecutive serum creatinine level baseline period meet following requirement : Women : 80 umol/l 250 umol/l ( inclusive ) Men : 105 umol/l 250 umol/l ( inclusive ) 5 . Written inform consent Pregnancy Known allergy cilostazol aspirin Congestive heart failure ( NYHA class III IV ) Severe liver impairment ( great equal 3 time ULN ALT ) Serum potassium level great equal 5.5 mmol/l 2 consecutive specimen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>Macroalbuminuria</keyword>
	<keyword>Pletaal</keyword>
</DOC>